Yi‐Mi Wu

7.5k total citations · 2 hit papers
44 papers, 2.5k citations indexed

About

Yi‐Mi Wu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Yi‐Mi Wu has authored 44 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 13 papers in Pulmonary and Respiratory Medicine and 12 papers in Cancer Research. Recurrent topics in Yi‐Mi Wu's work include Cancer Genomics and Diagnostics (10 papers), Prostate Cancer Treatment and Research (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Yi‐Mi Wu is often cited by papers focused on Cancer Genomics and Diagnostics (10 papers), Prostate Cancer Treatment and Research (6 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (5 papers). Yi‐Mi Wu collaborates with scholars based in United States, Taiwan and Australia. Yi‐Mi Wu's co-authors include Dan R. Robinson, Su‐Fang Lin, Arul M. Chinnaiyan, Xuhong Cao, Marcin Cieślik, Lanbo Xiao, Sudhanshu Shukla, Yuping Zhang, Josh N. Vo and Alexey I. Nesvizhskii and has published in prestigious journals such as Nature, Cell and Journal of Clinical Oncology.

In The Last Decade

Yi‐Mi Wu

43 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Landscape of Circular RNA in Cancer

2019 1.2k citations Josh N. Vo, Marcin Cieślik et al. profile →
The protein tyrosine kinase family of the human genome

2000 830 citations Dan R. Robinson, Yi‐Mi Wu et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yi‐Mi Wu United States	10	1.9k	1.2k	361	297	209	44	2.5k
Olga A. Guryanova United States	17	2.0k 1.0×	1.1k 0.9×	645 1.8×	258 0.9×	281 1.3×	36	3.0k
Nabendu Pore United States	17	1.4k 0.7×	1.1k 0.9×	614 1.7×	287 1.0×	244 1.2×	26	2.3k
Scott M. Welford United States	24	1.6k 0.9×	1.2k 1.0×	418 1.2×	671 2.3×	278 1.3×	60	2.6k
Ingrid J. Apel United States	19	1.3k 0.7×	733 0.6×	561 1.6×	280 0.9×	211 1.0×	26	2.1k
W. Clay Gustafson United States	19	1.6k 0.8×	456 0.4×	487 1.3×	342 1.2×	125 0.6×	38	2.3k
Esther Hulleman Netherlands	28	2.3k 1.2×	875 0.7×	1.1k 3.0×	307 1.0×	307 1.5×	81	3.7k
David Cogdell United States	27	1.8k 1.0×	1.2k 1.0×	477 1.3×	328 1.1×	108 0.5×	47	2.6k
Eijiro Nakamura Japan	21	1.4k 0.8×	1.3k 1.1×	441 1.2×	524 1.8×	193 0.9×	36	2.3k
Allie Fu United States	22	1.3k 0.7×	743 0.6×	462 1.3×	263 0.9×	193 0.9×	30	2.1k
Paul Meltzer United States	7	1.8k 0.9×	824 0.7×	768 2.1×	235 0.8×	233 1.1×	10	2.4k

Countries citing papers authored by Yi‐Mi Wu

Since Specialization

Citations

This map shows the geographic impact of Yi‐Mi Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi‐Mi Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi‐Mi Wu more than expected).

Fields of papers citing papers by Yi‐Mi Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yi‐Mi Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi‐Mi Wu. The network helps show where Yi‐Mi Wu may publish in the future.

Co-authorship network of co-authors of Yi‐Mi Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Yi‐Mi Wu. A scholar is included among the top collaborators of Yi‐Mi Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yi‐Mi Wu. Yi‐Mi Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kandarpa, Malathi, Dan R. Robinson, Yi‐Mi Wu, et al.. (2024). Broad Next-Generation Integrated Sequencing of Myelofibrosis Identifies Disease-Specific and Age-Related Genomic Alterations. Clinical Cancer Research. 30(9). 1972–1983. 4 indexed citations

Abdulfatah, Eman, Khaleel I. Al‐Obaidy, Dan R. Robinson, et al.. (2023). Molecular characterization of large cell calcifying sertoli cell tumors: A multi-institutional study of 6 benign and 2 malignant tumors. Human Pathology. 144. 15–21. 3 indexed citations

Cani, Andi K., Chia‐Jen Liu, Elizabeth P. Darga, et al.. (2023). Abstract P4-02-04: Serial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importance. Cancer Research. 83(5_Supplement). P4–2. 1 indexed citations

Rebernick, Ryan J., Matthew McFarlane, Yi‐Mi Wu, et al.. (2023). Clinical impact of mutations in driver oncogenes and TP53/RB1 in advanced prostate cancer.. Journal of Clinical Oncology. 41(6_suppl). 263–263. 1 indexed citations

Morikawa, Aki, Peter Ulintz, Xu Cheng, et al.. (2023). Optimizing Precision Medicine for Breast Cancer Brain Metastases with Functional Drug Response Assessment. Cancer Research Communications. 3(6). 1093–1103. 2 indexed citations

Jacobs, Michelle F., et al.. (2022). Homozygous ATM mutation due to germline uniparental isodisomy in patient with T acute lymphoblastic leukemia and hepatosplenic T-cell lymphoma. Cancer Genetics. 266-267. 15–18. 1 indexed citations

Li, Christopher I., Yuping Zhang, Marcin Cieślik, et al.. (2021). Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. Clinical Cancer Research. 27(11). 3079–3093. 10 indexed citations

Cobain, Erin F., Michelle F. Jacobs, Yi‐Mi Wu, et al.. (2020). Tumor/normal genomic profiling in patients with metastatic solid tumors identifies pathogenic germline variants of therapeutic importance.. Journal of Clinical Oncology. 38(15_suppl). 1501–1501. 1 indexed citations

Cackowski, Frank C., Chandan Kumar‐Sinha, Rohit Mehra, et al.. (2020). Double-Negative Prostate Cancer Masquerading as a Squamous Cancer of Unknown Primary: A Clinicopathologic and Genomic Sequencing-Based Case Study. JCO Precision Oncology. 4(4). 1386–1392. 4 indexed citations

10.

Kumar‐Sinha, Chandan, Dan R. Robinson, Yi‐Mi Wu, et al.. (2019). Metastatic castration resistant prostate cancer with squamous cell, small cell, and sarcomatoid elements—a clinicopathologic and genomic sequencing-based discussion. Medical Oncology. 36(3). 27–27. 6 indexed citations

11.

Demirci, Hakan, F. Yesim Demirci, Victor M. Elner, et al.. (2019). Integrative Exome and Transcriptome Analysis of Conjunctival Melanoma and Its Potential Application for Personalized Therapy. JAMA Ophthalmology. 137(12). 1444–1444. 25 indexed citations

12.

Parolia, Abhijit, Marcin Cieślik, Lanbo Xiao, et al.. (2019). Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer. Nature. 571(7765). 413–418. 160 indexed citations

13.

Weyand, Angela C., et al.. (2018). Clinical Implications of Real-time Integrative Sequencing in Management of Patients With Suspected Germline BAP1 Mutations. Journal of Pediatric Hematology/Oncology. 41(4). e263–e265. 1 indexed citations

14.

Connelly, James A., Rajen Mody, Yi‐Mi Wu, et al.. (2018). Identification of novelMECOMgene fusion and personalized therapeutic targets through integrative clinical sequencing in secondary acute myeloid leukemia in a patient with severe congenital neutropenia: a case report and literature review. Molecular Case Studies. 4(2). a002204–a002204. 2 indexed citations

15.

Vo, Josh N., Yajia Zhang, Sudhanshu Shukla, et al.. (2018). Abstract 3288: The landscape of circular RNA in cancer. Cancer Research. 78(13_Supplement). 3288–3288. 2 indexed citations

16.

Cobain, Erin F., Dan R. Robinson, Yi‐Mi Wu, et al.. (2017). Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults.. Journal of Clinical Oncology. 35(15_suppl). 101–101. 7 indexed citations

17.

Koschmann, Carl, Alan Mackay, Dan R. Robinson, et al.. (2016). GENT-10. CHARACTERIZING AND TARGETING PDGFRA ALTERATIONS IN PEDIATRIC HIGH-GRADE GLIOMA. Neuro-Oncology. 18(suppl_6). vi75–vi75. 1 indexed citations

18.

Weyand, Angela C., Gregory A. Yanik, Nathanael G. Bailey, et al.. (2015). Imatinib Treatment in PDGFRA‐Negative Childhood Hypereosinophilic Syndrome. Pediatric Blood & Cancer. 63(1). 164–167. 1 indexed citations

19.

Wu, Yi‐Mi, et al.. (1996). Molecular Analysis of cDNA Molecules Encoding Glutamate Receptor Subunits, fGluR1α and fGluR1β, of Oreochromis sp.. DNA and Cell Biology. 15(9). 717–725. 10 indexed citations

20.

Wu, Yi‐Mi, et al.. (1996). Characterization of two fish glutamate receptor cDNA molecules: absence of RNA editing at the Q/R site. Molecular Brain Research. 35(1-2). 119–130. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact